International Journal of Tumor Research

International Journal of Tumor Research

Open Access
ISSN: 3070-3948
Research Article

Level of the Serum Adiponectin as a Biochemical Marker of Liver Fibrosis in Hepatitis C Patients

Authors: Mahmoud Saad Berengy, Abd El- Monem Gaballah, Abd El- Mohsen Shaheen, Khaled El-Mola, Hany Awadallah,Mohamed Heiza, Mohamed Ali Awad Gad

DOI: 10.33425/3070-3948.1002


Abstract

Background: Adiponectin is a protein hormone secreted by adipose tissue. There is no data about the secretion of adiponectin during hepatitis C infection; some studies revealed that hyperadiponectinemia found with chronic HCV infection is significantly associated with the development of liver fibrosis. Nonetheless, the action of adiponectin in chronic HCV infection is still controversial.

Objective: measurement of the serum adiponectin as a biochemical marker of liver fibrosis in hepatitis C patients.

Subjects and Methods: The present study was conducted on sixty patients suffering from chronic hepatitis C and twenty eight healthy volunteers served as controls.

Results: The significant finding of this study is that chronic HCV patients have increased circulating adiponectin levels than healthy controls (9.16 ± 6.72 for HCV vs. 4.12 ± 1.78 for control, p <0.05) and it can be used as a biochemical marker for grade 4 fibrosis in metavir score which indicate cirrhosis while no significant difference between non cirrhotic grades and control group, also, adiponectin correlates positively with grade of fibrosis.

Conclusion: This study demonstrated that hyperadiponectinaemia in HCV-infected patients correlate with hepatic fibrosis and it can be used as a biochemical marker for grade 4 fibrosis in metavir score which indicates cirrhosis.

View / Download PDF
Citation: Mahmoud Saad Berengy, Abd El- Monem Gaballah, Abd El- Mohsen Shaheen, et al. Level of the Serum Adiponectin as a Biochemical Marker of Liver Fibrosis in Hepatitis C Patients. 2025; 1(1). DOI: 10.33425/3070-3948.1002
Editor-in-Chief
 Darren R Carpizo
Darren R Carpizo
Division of Surgical Oncology | University of Rochester Medical Center

View full editorial board →
Journal Metrics
Impact Factor 2.03*
Acceptance Rate 75%
Time to first decision 6- 10 Days
Submission to acceptance 12- 15 Days